Biotech IV Monitor

CGON — CG Oncology, Inc.

$6.1B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for CG Oncology, Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.

Next readoutMarch 2027in ~4 months
Upcoming readouts21 Phase 3
Market cap$6.1B
Cash & investments$984M~17 quarters at last loss rate
Recent 8-K filings2latest 2026-11-16

Upcoming readouts

Phase 2 Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer · NCT06567743
March 2027
Recruiting
Phase 3 Cretostimogene Grenadenorepvec
Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer · NCT04452591
June 2030
Ongoing

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 3 Cretostimogene Grenadenorepvec
Non Muscle Invasive Bladder Cancer; Urologic Cancer · NCT06111235
November 2026
Ongoing

Cash position

CG Oncology, Inc. reported $984M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-06). Its net loss for that quarter was $57M; at that rate the cash would last about 17 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-16
8-K Results of Operations — earnings, may carry pipeline updates2026-11-06

Companies working on similar indications

Discussion

No messages yet. If you follow CGON, you can start the conversation.
Track CGON in real time
See live implied volatility for CGON and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on CGON
Contact — questions or corrections about CGON: dukeupt@gmail.com